Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shengmai Liquid for Long COVID Fatigue
NCT06980636Phase 4Recruiting
- Sponsor
- Beijing University of Chinese Medicine
- Start
- Dec 2025
- Primary completion
- Oct 2026
- Modality
- HM (Herbal Medicine), Oral liquid
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in post-acute sequelae of SARS-CoV-2 infection (PASC) comparing Shengmai Liquid with Placebo (2 arms). Primary endpoint: Modified Fatigue Impact Scale at 12 weeks. Started Dec 2025; status: recruiting.
02
Drugs
Shengmai Liquid
03
Conditions
post-acute sequelae of SARS-CoV-2 infection (PASC)
Beyond the preview
Go deeper on NCT06980636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06980636.